

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-35. (Canceled)

36. (Previously Presented) A liposomal formulation, said liposomal formulation comprising a liposome having vinorelbine in solution and precipitated vinorelbine, wherein the precipitated vinorelbine in said liposome is at least 50% of the total vinorelbine, wherein said liposome comprises sphingomyelin and cholesterol at a ratio in the range of about 75/25 mol%/mol% sphingomyelin/cholesterol to about 30/50 mol%/mol% sphingomyelin/cholesterol, and wherein the ratio of said vinorelbine to lipid is 0.1-0.5:1 (w/w).

37.-42. (Canceled)

43. (Previously Presented) The liposomal formulation of claim 36, wherein said liposome comprises sphingomyelin and cholesterol in a 55:45 molar ratio.

44.-65. (Canceled)

66. (Previously Presented) The liposomal formulation of claim 36, wherein the ratio of said vinorelbine to said lipid is about 0.1-0.3:1 (w/w).

67. (Previously Presented) The liposomal formulation of claim 36, wherein said liposome comprises sphingomyelin and cholesterol in a 50:50 molar ratio.

68. (Previously Presented) The liposomal formulation of claim 66, wherein the ratio of said vinorelbine to said lipid is about 0.3:1 (w/w).

69. (New) The liposomal formulation of claim 36, wherein the ratio of said vinorelbine to said lipid is 0.2-0.5:1 (w/w).

70. (New) The liposomal formulation of claim 36, wherein the ratio of said vinorelbine to said lipid is 0.3-0.5:1 (w/w).